Released Jun 1, 2020, before the open
10-Q filed Jun 1, 2020, 62 days after period end · 0001104659-20-067982
Q1 2020 · 10-Q
Revenue$21.65M$21.65M +107.4% vs Q1 2019+21.9% vs Q4 2019
Net Income$1.67M$1.67M N/M vs Q1 2019+472.9% vs Q4 2019
EPS Diluted$0.10$0.10 N/M vs Q1 2019+400.0% vs Q4 2019
Operating Income$4,693,000N/M
Operating Cash Flow-$7,117,000N/M
Free Cash Flowderived-$7,183,000N/M
Margins · derived
Operating margin21.7%+74.7 pt vs Q1 2019
Net margin7.7%+77.3 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $21.65M | $10.44M | $4.55M | $2.89M |
| Net Income | $1.67M | -$7.26M | -$7.24M | -$59.15M |
| EPS Diluted | $0.10 | -$0.50 | -$0.50 | -$0.48 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Protalix BioTherapeutics, Inc. · CIK 1006281 · Engraved from SEC EDGAR